Shizuoka, Japan

Kazuhisa Ozeki

This inventor holds 1 USPTO granted patent and 5 published patent applications and 1 EPO patent. Top assignee: Chugai Seiyaku Kabushiki Kaisha. Active years: 2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kazuhisa Ozeki. Retrieved from https://idiyas.com/inventor/kazuhisa-ozeki

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 1 

% Patents Active = 100.0

 

Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Kazuhisa Ozeki: Innovator in Pharmaceutical Development

Introduction

Kazuhisa Ozeki is a notable inventor based in Gotemba-shi, Shizuoka, Japan. He is associated with Chugai Seiyaku Kabushiki Kaisha, a prominent company in the pharmaceutical industry. Although he currently holds no patents, his contributions to the field of pharmaceuticals are significant.

Latest Patents

As of now, Kazuhisa Ozeki has not registered any patents. However, his work in the pharmaceutical sector continues to influence the development of innovative solutions.

Career Highlights

Kazuhisa Ozeki has dedicated his career to advancing pharmaceutical research and development. His role at Chugai Seiyaku Kabushiki Kaisha has allowed him to collaborate with various teams to enhance drug formulations and therapeutic strategies.

Collaborations

Due to space constraints, the details of collaborations will not be included.

Conclusion

Kazuhisa Ozeki remains a key figure in the pharmaceutical industry, contributing to advancements that may lead to future innovations. His work exemplifies the importance of dedication and collaboration in the field of medicine.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…